ID   SU-DHL-6
AC   CVCL_2206
SY   SUDHL6; SuDHL6; SU-DHL6; SUDHL-6; SuDHL-6; Sudhl-6; SUD6; Stanford University-Diffuse Histiocytic Lymphoma-6; DHL-6; DHL6
DR   CLO; CLO_0037063
DR   EFO; EFO_0002357
DR   AddexBio; C0003011/4672
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   ATCC; CRL-2959
DR   BioSample; SAMN03471138
DR   BioSample; SAMN10989551
DR   cancercelllines; CVCL_2206
DR   CCRID; 5301HUM-KCB1629YJA
DR   CCTCC; GDC0164
DR   Cell_Model_Passport; SIDM00407
DR   ChEMBL-Cells; CHEMBL4295461
DR   Cosmic; 687854
DR   Cosmic; 850205
DR   Cosmic; 1070712
DR   Cosmic; 1329089
DR   Cosmic; 1517640
DR   Cosmic; 1541911
DR   Cosmic; 1629935
DR   Cosmic; 1636688
DR   Cosmic; 1714158
DR   Cosmic; 2276340
DR   Cosmic; 2297009
DR   Cosmic; 2437315
DR   Cosmic-CLP; 1331037
DR   DepMap; ACH-000611
DR   DSMZ; ACC-572
DR   DSMZCellDive; ACC-572
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   EGA; EGAS00001002554
DR   ENCODE; ENCBS107PVI
DR   ENCODE; ENCBS136LHJ
DR   ENCODE; ENCBS401ZBX
DR   ENCODE; ENCBS782RBW
DR   GDSC; 1331037
DR   GEO; GSM1955
DR   GEO; GSM115975
DR   GEO; GSM201348
DR   GEO; GSM380147
DR   GEO; GSM552465
DR   GEO; GSM887655
DR   GEO; GSM888747
DR   GEO; GSM1035311
DR   GEO; GSM1374908
DR   GEO; GSM1670487
DR   IARC_TP53; 28323
DR   IGRhCellID; SUDHL6
DR   KCB; KCB 2016029YJ-A
DR   LiGeA; CCLE_578
DR   LINCS_LDP; LCL-1138
DR   Lonza; 942
DR   MetaboLights; MTBLS774
DR   PharmacoDB; SUDHL6_1504_2019
DR   PRIDE; PXD000589
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_2206
DR   PubChem_Cell_line; CVCL_2206
DR   Wikidata; Q54970721
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=83902;
RX   PubMed=177185;
RX   PubMed=214220;
RX   PubMed=371794;
RX   PubMed=3881165;
RX   PubMed=7849311;
RX   PubMed=9738977;
RX   PubMed=9787181;
RX   PubMed=10676951;
RX   PubMed=12169673;
RX   PubMed=15122589;
RX   PubMed=16960149;
RX   PubMed=19278952;
RX   PubMed=20054396;
RX   PubMed=20215515;
RX   PubMed=20628145;
RX   PubMed=20889926;
RX   PubMed=22460905;
RX   PubMed=23699601;
RX   PubMed=25355872;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25894527;
RX   PubMed=25960936;
RX   PubMed=26589293;
RX   PubMed=26727417;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
RX   PubMed=31395879;
RX   PubMed=31978347;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: TCGA-110-CL cell line panel.
CC   Population: Caucasian.
CC   Doubling time: ~35-40 hours (DSMZ=ACC-572).
CC   HLA typing: A*11 (PubMed=25960936).
CC   HLA typing: A*02:01,23:01; B*15:01,49:01; C*03:03,07:06 (PubMed=26589293).
CC   HLA typing: A*02:01:01,23:01:01; B*15:01:01,49:01:01; C*03:03:01,07:01:01; DPA1*01:03:01,01:03:01; DPB1*04:02:01,04:01:01; DQA1*01:02:01,03:01:01; DQB1*03:02:01,05:02:01; DRA*01:01:01,01:01:02; DRB1*01:01:01,04:01:01 (DSMZCellDive=ACC-572).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; 990; BCL2 + HGNC; 5477; IGH; Name(s)=IGH-BCL2 (DSMZ=ACC-572).
CC   Sequence variation: Mutation; HGNC; 3527; EZH2; Simple; p.Tyr646Ser (c.1937A>C) (Y641S); ClinVar=VCV000376218; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gln211Ter (c.631C>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Glu4712Ter (c.14134G>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.673-2A>C (IVS6-2A>C); ClinVar=VCV000635387; Zygosity=Heterozygous; Note=Splice acceptor mutation (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234Cys (c.701A>G); ClinVar=VCV000127820; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: Cell surface proteome.
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Genome sequenced.
CC   Omics: H3K9ac ChIP-seq epigenome analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Omics: Virome analysis using RNAseq.
CC   Genome ancestry: African=2.74%; Native American=0%; East Asian, North=1.8%; East Asian, South=0%; South Asian=0%; European, North=59.44%; European, South=36.02% (PubMed=30894373).
CC   Derived from site: In situ; Peritoneal effusion; UBERON=UBERON_0001268.
ST   Source(s): AddexBio; ATCC; CCRID; Cosmic-CLP; DSMZ; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 12,14
ST   D16S539: 11,12
ST   D18S51: 12,13
ST   D19S433: 14
ST   D21S11: 29
ST   D2S1338: 18,19
ST   D3S1358: 14,17
ST   D5S818: 12
ST   D7S820: 10
ST   D8S1179: 14
ST   FGA: 20,24
ST   Penta D: 8,10
ST   Penta E: 5,12
ST   TH01: 6,9.3
ST   TPOX: 11,12
ST   vWA: 14,17
DI   NCIt; C36080; Diffuse large B-cell lymphoma germinal center B-cell type
DI   ORDO; Orphanet_544; Diffuse large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   43Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 44
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=83902; DOI=10.1002/1097-0142(197901)43:1<1::AID-CNCR2820430102>3.0.CO;2-M;
RA   Kaplan H.S., Goodenow R.S., Gartner S., Bieber M.M.;
RT   "Biology and virology of the human malignant lymphomas: 1st Milford D.
RT   Schulz Lecture.";
RL   Cancer 43:1-24(1979).
//
RX   PubMed=177185; DOI=10.1002/1097-0142(197605)37:5<2158::AID-CNCR2820370503>3.0.CO;2-F;
RA   Epstein A.L., Herman M.M., Kim H., Dorfman R.F., Kaplan H.S.;
RT   "Biology of the human malignant lymphomas. III. Intracranial
RT   heterotransplantation in the nude, athymic mouse.";
RL   Cancer 37:2158-2176(1976).
//
RX   PubMed=214220; DOI=10.1002/1097-0142(197811)42:5<2379::AID-CNCR2820420539>3.0.CO;2-4;
RA   Epstein A.L., Levy R., Kim H., Henle W., Henle G., Kaplan H.S.;
RT   "Biology of the human malignant lymphomas. IV. Functional
RT   characterization of ten diffuse histiocytic lymphoma cell lines.";
RL   Cancer 42:2379-2391(1978).
//
RX   PubMed=371794;
RA   Epstein A.L., Kaplan H.S.;
RT   "Feeder layer and nutritional requirements for the establishment and
RT   cloning of human malignant lymphoma cell lines.";
RL   Cancer Res. 39:1748-1759(1979).
//
RX   PubMed=3881165; DOI=10.1016/0165-4608(85)90186-4;
RA   Kaiser-McCaw Hecht B., Epstein A.L., Berger C.S., Kaplan H.S.,
RA   Hecht F.;
RT   "Histiocytic lymphoma cell lines: immunologic and cytogenetic
RT   studies.";
RL   Cancer Genet. Cytogenet. 14:205-218(1985).
//
RX   PubMed=7849311; DOI=10.1182/blood.V85.4.893.bloodjournal854893;
RA   Stranks G., Height S.E., Mitchell P., Jadayel D.M., Yuille M.A.R.,
RA   De Lord C., Clutterbuck R.D., Treleaven J.G., Powles R.L.,
RA   Nacheva E., Oscier D.G., Karpas A., Lenoir G.M., Smith S.D.,
RA   Millar J.L., Catovsky D., Dyer M.J.S.;
RT   "Deletions and rearrangement of CDKN2 in lymphoid malignancy.";
RL   Blood 85:893-901(1995).
//
RX   PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x;
RA   Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T.,
RA   Aizawa Y., Ueda R., Seto M.;
RT   "Expression of the TCL1 gene at 14q32 in B-cell malignancies but not
RT   in adult T-cell leukemia.";
RL   Jpn. J. Cancer Res. 89:712-718(1998).
//
RX   PubMed=9787181; DOI=10.1182/blood.V92.9.3410;
RA   Sakai A., Thieblemont C., Wellmann A., Jaffe E.S., Raffeld M.;
RT   "PTEN gene alterations in lymphoid neoplasms.";
RL   Blood 92:3410-3415(1998).
//
RX   PubMed=10676951; DOI=10.1038/35000501;
RA   Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S.,
RA   Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X., Powell J.I.,
RA   Yang L.-M., Marti G.E., Moore T., Hudson J. Jr., Lu L.-S., Lewis D.B.,
RA   Tibshirani R., Sherlock G., Chan W.C., Greiner T.C.,
RA   Weisenburger D.D., Armitage J.O., Warnke R.A., Levy R., Wilson W.,
RA   Grever M.R., Byrd J.C., Botstein D., Brown P.O., Staudt L.M.;
RT   "Distinct types of diffuse large B-cell lymphoma identified by gene
RT   expression profiling.";
RL   Nature 403:503-511(2000).
//
RX   PubMed=12169673; DOI=10.1016/S1525-1578(10)60693-9;
RA   Robetorye R.S., Bohling S.D., Morgan J.W., Fillmore G.C., Lim M.S.,
RA   Elenitoba-Johnson K.S.J.;
RT   "Microarray analysis of B-cell lymphoma cell lines with the
RT   t(14;18).";
RL   J. Mol. Diagn. 4:123-136(2002).
//
RX   PubMed=15122589; DOI=10.1002/ijc.20170;
RA   Liggins A.P., Guinn B.A., Hatton C.S., Pulford K., Banham A.H.;
RT   "Serologic detection of diffuse large B-cell lymphoma-associated
RT   antigens.";
RL   Int. J. Cancer 110:563-569(2004).
//
RX   PubMed=16960149; DOI=10.1182/blood-2006-06-026500;
RA   Mestre-Escorihuela C., Rubio-Moscardo F., Richter J.A., Siebert R.,
RA   Climent J., Fresquet V., Beltran E., Agirre X., Marugan I., Marin M.,
RA   Rosenwald A., Sugimoto K.-j., Wheat L.M., Karran E.L., Garcia J.F.,
RA   Sanchez-Verde L., Prosper F., Staudt L.M., Pinkel D., Dyer M.J.S.,
RA   Martinez-Climent J.A.;
RT   "Homozygous deletions localize novel tumor suppressor genes in B-cell
RT   lymphomas.";
RL   Blood 109:271-280(2007).
//
RX   PubMed=19278952; DOI=10.1182/blood-2009-01-202028;
RA   Li C., Kim S.-W., Rai D., Bolla A.R., Adhvaryu S., Kinney M.C.,
RA   Robetorye R.S., Aguiar R.C.T.;
RT   "Copy number abnormalities, MYC activity, and the genetic fingerprint
RT   of normal B cells mechanistically define the microRNA profile of
RT   diffuse large B-cell lymphoma.";
RL   Blood 113:6681-6690(2009).
//
RX   PubMed=20054396; DOI=10.1038/nature08638;
RA   Davis R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B.,
RA   Kohlhammer H., Lamy L., Zhao H., Yang Y.-D., Xu W.-H., Shaffer A.L. III,
RA   Wright G., Xiao W.-M., Powell J.I., Jiang J.-K., Thomas C.J., Rosenwald A.,
RA   Ott G., Muller-Hermelink H.-K., Gascoyne R.D., Connors J.M.,
RA   Johnson N.A., Rimsza L.M., Campo E., Jaffe E.S., Wilson W.H.,
RA   Delabie J., Smeland E.B., Fisher R.I., Braziel R.M., Tubbs R.R.,
RA   Cook J.R., Weisenburger D.D., Chan W.C., Pierce S.K., Staudt L.M.;
RT   "Chronic active B-cell-receptor signalling in diffuse large B-cell
RT   lymphoma.";
RL   Nature 463:88-92(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20628145; DOI=10.1182/blood-2010-05-282780;
RA   Green M.R., Monti S., Rodig S.J., Juszczynski P., Currie T.,
RA   O'Donnell E., Chapuy B., Takeyama K., Neuberg D., Golub T.R.,
RA   Kutok J.L., Shipp M.A.;
RT   "Integrative analysis reveals selective 9p24.1 amplification,
RT   increased PD-1 ligand expression, and further induction via JAK2 in
RT   nodular sclerosing Hodgkin lymphoma and primary mediastinal large
RT   B-cell lymphoma.";
RL   Blood 116:3268-3277(2010).
//
RX   PubMed=20889926; DOI=10.1182/blood-2010-06-290437;
RA   Pham L.V., Fu L.-C., Tamayo A.T., Bueso-Ramos C.E., Drakos E.,
RA   Vega-Vazquez F., Medeiros L.J., Ford R.J. Jr.;
RT   "Constitutive BR3 receptor signaling in diffuse, large B-cell
RT   lymphomas stabilizes nuclear factor-kappaB-inducing kinase while
RT   activating both canonical and alternative nuclear factor-kappaB
RT   pathways.";
RL   Blood 117:200-210(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23699601; DOI=10.1182/blood-2013-02-483727;
RA   Morin R.D., Mungall K., Pleasance E.D., Mungall A.J., Goya R.,
RA   Huff R.D., Scott D.W., Ding J.-R., Roth A., Chiu R., Corbett R.D.,
RA   Chan F.C., Mendez-Lago M., Trinh D.L., Bolger-Munro M., Taylor G.,
RA   Hadj Khodabakhshi A., Ben-Neriah S., Pon J., Meissner B., Woolcock B.,
RA   Farnoud N., Rogic S., Lim E.L., Johnson N.A., Shah S., Jones S.J.M.,
RA   Steidl C., Holt R.A., Birol I., Moore R., Connors J.M., Gascoyne R.D.,
RA   Marra M.A.;
RT   "Mutational and structural analysis of diffuse large B-cell lymphoma
RT   using whole-genome sequencing.";
RL   Blood 122:1256-1265(2013).
//
RX   PubMed=25355872; DOI=10.1128/JVI.02570-14;
RA   Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z.,
RA   O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.;
RT   "High-throughput RNA sequencing-based virome analysis of 50 lymphoma
RT   cell lines from the Cancer Cell Line Encyclopedia project.";
RL   J. Virol. 89:713-729(2015).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25894527; DOI=10.1371/journal.pone.0121314;
RA   Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F.,
RA   Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R.,
RA   Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P.,
RA   Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.;
RT   "A mass spectrometric-derived cell surface protein atlas.";
RL   PLoS ONE 10:E0121314-E0121314(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=26727417; DOI=10.3109/10428194.2015.1108414;
RA   Drexler H.G., Eberth S., Nagel S., MacLeod R.A.F.;
RT   "Malignant hematopoietic cell lines: in vitro models for double-hit
RT   B-cell lymphomas.";
RL   Leuk. Lymphoma 57:1015-1020(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=31395879; DOI=10.1038/s41467-019-11415-2;
RA   Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M.,
RA   van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.;
RT   "Comprehensive transcriptomic analysis of cell lines as models of
RT   primary tumors across 22 tumor types.";
RL   Nat. Commun. 10:3574.1-3574.11(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//